Revisiting the Cholinergic Hypothesis in Alzheimer's Disease

Emerging Evidence from Translational and Clinical Research

H. Hampel, M. M. Mesulam, A. C. Cuello, A. S. Khachaturian, A. Vergallo, Martin Farlow, P. J. Snyder, E. Giacobini, Z. S. Khachaturian

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "Cholinergic Hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system as one of several interacting systems failures that contribute to AD pathogenesis.

Original languageEnglish (US)
Pages (from-to)2-15
Number of pages14
JournalThe journal of prevention of Alzheimer's disease
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Translational Medical Research
Cholinergic Agents
Alzheimer Disease
Cholinesterase Inhibitors
Neuroimaging
Cerebral Cortex
Atrophy
Therapeutics
Brain

Keywords

  • Alzheimer’s disease
  • basal forebrain cholinergic system atrophy
  • cholinergic system
  • cholinesterase inhibitors
  • nerve growth factor
  • nucleus basalis of Meynert (NbM) degeneration

Cite this

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease : Emerging Evidence from Translational and Clinical Research. / Hampel, H.; Mesulam, M. M.; Cuello, A. C.; Khachaturian, A. S.; Vergallo, A.; Farlow, Martin; Snyder, P. J.; Giacobini, E.; Khachaturian, Z. S.

In: The journal of prevention of Alzheimer's disease, Vol. 6, No. 1, 01.01.2019, p. 2-15.

Research output: Contribution to journalArticle

Hampel, H, Mesulam, MM, Cuello, AC, Khachaturian, AS, Vergallo, A, Farlow, M, Snyder, PJ, Giacobini, E & Khachaturian, ZS 2019, 'Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research', The journal of prevention of Alzheimer's disease, vol. 6, no. 1, pp. 2-15. https://doi.org/10.14283/jpad.2018.43
Hampel, H. ; Mesulam, M. M. ; Cuello, A. C. ; Khachaturian, A. S. ; Vergallo, A. ; Farlow, Martin ; Snyder, P. J. ; Giacobini, E. ; Khachaturian, Z. S. / Revisiting the Cholinergic Hypothesis in Alzheimer's Disease : Emerging Evidence from Translational and Clinical Research. In: The journal of prevention of Alzheimer's disease. 2019 ; Vol. 6, No. 1. pp. 2-15.
@article{a23e2964d8914b5e98e96b31b5aea3ef,
title = "Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research",
abstract = "Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the {"}Cholinergic Hypothesis of AD{"} and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system as one of several interacting systems failures that contribute to AD pathogenesis.",
keywords = "Alzheimer’s disease, basal forebrain cholinergic system atrophy, cholinergic system, cholinesterase inhibitors, nerve growth factor, nucleus basalis of Meynert (NbM) degeneration",
author = "H. Hampel and Mesulam, {M. M.} and Cuello, {A. C.} and Khachaturian, {A. S.} and A. Vergallo and Martin Farlow and Snyder, {P. J.} and E. Giacobini and Khachaturian, {Z. S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.14283/jpad.2018.43",
language = "English (US)",
volume = "6",
pages = "2--15",
journal = "The journal of prevention of Alzheimer's disease",
issn = "2426-0266",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Revisiting the Cholinergic Hypothesis in Alzheimer's Disease

T2 - Emerging Evidence from Translational and Clinical Research

AU - Hampel, H.

AU - Mesulam, M. M.

AU - Cuello, A. C.

AU - Khachaturian, A. S.

AU - Vergallo, A.

AU - Farlow, Martin

AU - Snyder, P. J.

AU - Giacobini, E.

AU - Khachaturian, Z. S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "Cholinergic Hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system as one of several interacting systems failures that contribute to AD pathogenesis.

AB - Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment. This evidence led to the formulation of the "Cholinergic Hypothesis of AD" and the development of cholinesterase inhibitor therapies. Although approved only as symptomatic therapies, recent studies suggest that long-term use of these drugs may also have disease-modifying benefits. A Cholinergic System Workgroup reassessed the role of the cholinergic system on AD pathogenesis in light of recent data, including neuroimaging data charting the progression of neurodegeneration in the cholinergic system and suggesting that cholinergic therapy may slow brain atrophy. Other pathways that contribute to cholinergic synaptic loss and their effect on cognitive impairment in AD were also reviewed. These studies indicate that the cholinergic system as one of several interacting systems failures that contribute to AD pathogenesis.

KW - Alzheimer’s disease

KW - basal forebrain cholinergic system atrophy

KW - cholinergic system

KW - cholinesterase inhibitors

KW - nerve growth factor

KW - nucleus basalis of Meynert (NbM) degeneration

UR - http://www.scopus.com/inward/record.url?scp=85058851988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058851988&partnerID=8YFLogxK

U2 - 10.14283/jpad.2018.43

DO - 10.14283/jpad.2018.43

M3 - Article

VL - 6

SP - 2

EP - 15

JO - The journal of prevention of Alzheimer's disease

JF - The journal of prevention of Alzheimer's disease

SN - 2426-0266

IS - 1

ER -